Daniel W. Muehl
2007 - Repligen
In 2007, Daniel W. Muehl earned a total compensation of $369.2K as Chief Financial Officer at Repligen.
Compensation breakdown
| Non-Equity Incentive Plan | $33,440 |
|---|---|
| Option Awards | $101,347 |
| Salary | $200,000 |
| Stock Awards | $33,176 |
| Other | $1,200 |
| Total | $369,163 |
Muehl received $200K in salary, accounting for 54% of the total pay in 2007.
Muehl also received $33.4K in non-equity incentive plan, $101.3K in option awards, $33.2K in stock awards and $1.2K in other compensation.
Rankings
In 2007, Daniel W. Muehl's compensation ranked 6,938th out of 8,700 executives tracked by ExecPay. In other words, Muehl earned more than 20.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,938 out of 8,700 | 20th |
Division Manufacturing | 2,665 out of 3,314 | 20th |
Major group Chemicals And Allied Products | 608 out of 746 | 19th |
Industry group Drugs | 436 out of 546 | 20th |
Industry Biological Products, Except Diagnostic Substances | 86 out of 118 | 27th |
Source: SEC filing on July 29, 2008.
Muehl's colleagues
We found three more compensation records of executives who worked with Daniel W. Muehl at Repligen in 2007.
News
Clovis Oncology CEO Patrick Mahaffy's 2021 pay slips 18% to $2.6M
April 27, 2022
Clovis Oncology CEO Patrick Mahaffy's 2020 pay falls 53% to $3.2M
April 28, 2021
Clovis Oncology CEO Patrick Mahaffy's 2019 pay rises 10% to $6.9M
April 24, 2020
Clovis Oncology CEO Patrick Mahaffy's 2018 pay falls 28% to $6.3M
April 26, 2019